| EVOLUS INC. DL-,00001 |
| USA |
| Gesundheit |
| US30052C1071 / A2JDYX |
| EVL (Frankfurt) / EOLS (NASDAQ) |
| FRA:EVL, ETR:EVL, EVL:GR, NASDAQ:EOLS |
| - |
| https://www.evolus.com/ |
|
Evolus Inc. is a performance beauty company focused on the cash-pay medical aesthetics market. Evolus Inc. markets Jeuveau, a proprietary neurotoxin used by licensed aesthetic practitioners for temporary improvement in the appearance of moderate to s..
>Volltext.. |
| 469.86 Mio. EUR |
| 575.38 Mio. EUR |
| 281.42 Mio. EUR |
| -9.21 Mio. EUR |
| -30.53 Mio. EUR |
| -0.47 EUR |
| 146.54 Mio. EUR |
| 40.17 Mio. EUR |
| -13.68 Mio. EUR |
| 0.46 |
| 17.45% |
| 42.88% |
| - |
| - |
| - |
| EVOLUS |
| 02.10.26 |
|